On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s | ...

This episode of Pharma Pulse discusses a new executive order to build a domestic API stockpile, Eli Lilly’s 170% price ...

Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets. The ...

Nike co-founder Phil Knight and his wife, Penny Knight, are donating $2 billion to Oregon Health & Science University's Knight Cancer Institute, the largest known single gift to a U.S. university. The ...